Navigation Links
Clinical Trial Participation Today May Lead To Future Breakthroughs In Pancreatic Cancer, One Of The Nation's Deadliest Cancers
Date:1/6/2014

MANHATTAN BEACH, Calif., Jan. 6, 2014 /PRNewswire/ -- January marks the annual observance of National Pancreatic Cancer Clinical Trials Awareness Month.  The five year survival rate of pancreatic cancer is just six percent. In the effort to highlight the urgent need to improve the survival rate for this disease, the Pancreatic Cancer Action Network is educating the public about clinical trials and the critical role they play in making scientific progress.

(Logo: http://photos.prnewswire.com/prnh/20111004/LA79914LOGO)

In particular for pancreatic cancer, with few effective treatment options for patients, clinical trials are an extremely important part of the research process as scientists seek new, better treatments that will ultimately increase survival. Studies have determined that both a lack of awareness and low prioritization of clinical trials by physicians and patients facing cancer contribute to the low enrollment rates.

"Clinical trials are the way to make progress towards better treatments – participation today will shape the treatment landscape for the future," says Julie Fleshman, president and CEO of the Pancreatic Cancer Action Network. "In addition to being treated with new and innovative therapies, patients will be making a contribution to science by helping researchers learn more about the disease and help improve cancer care."

In 2013, nearly 45,000 Americans were diagnosed with pancreatic cancer and more than 38,000 died from the disease. A recent analysis reveals that pancreatic cancer is projected to move from the fourth to the second leading cause of cancer death in the United States by the year 2020.  Now more than ever, we need to change the course of pancreatic cancer.

"It is also essential for patients to know, that in all pancreatic cancer trials, patients always receive either the best standard treatment or the treatment being evaluated in the trial," adds Fleshman. "Thanks to clinical trial research and participation, significant advancements in the field of pancreatic cancer have been made. However, much still lies ahead."

To bring attention to the need for clinical trials and to increase enrollment, the organization's Patient and Liaison Services (PALS) program educates patients and caregivers about their options and the value of clinical trials. The program also conducts personalized searches using the organization's comprehensive, proprietary clinical trials database to determine potential eligibility. This database is the nation's leading resource for pancreatic cancer clinical trials.

To learn more about the Pancreatic Cancer Action Network, the PALS program and clinical trials, visit www.pancan.org/pals.

About the Pancreatic Cancer Action Network
The Pancreatic Cancer Action Network is the national organization creating hope in a comprehensive way through research, patient support, community outreach and advocacy for a cure. The organization is leading the way to increase the survival rate for people diagnosed with this devastating disease through a bold initiative — The Vision of Progress: Double the Pancreatic Cancer Survival Rate by 2020. Together, we can know, fight and end pancreatic cancer by intensifying our efforts to heighten awareness, raise funds for comprehensive private research, and advocate for dedicated federal research to advance early diagnostics, better treatments and increase chances of survival.

Contact:
Anne Milo
Public Relations Manager
Pancreatic Cancer Action Network
Direct: 310-706-3357
Cell: 562-810-3016
Email: amilo@pancan.org

Video with caption: "January is National Pancreatic Cancer Clinical Trials Awareness Month, and you can help make progress in pancreatic cancer by spreading the word about the need for clinical research. With increased research and participation in clinical trials, we can learn faster and improve pancreatic cancer patient outcomes. To learn more about the Pancreatic Cancer Action Network, the PALS program and clinical trials, visit www.pancan.org." Video available at: http://www.youtube.com/watch?v=1Q33kPoZNKM


'/>"/>
SOURCE Pancreatic Cancer Action Network
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. TauRx Expands Alzheimers Clinical Trials in the United States
2. ideaPoint, Inc. Announces Launch of Multi-Sponsor Portal Providing Researchers Opportunity to Request Access to Clinical Data from Five Global Study Sponsors
3. Cell Therapeutics Announces Removal of the Partial Clinical Hold on Tosedostat
4. CMC Biologics and OncoSynergy Enter into Agreement to Develop and Manufacture Material for IND Enabling Studies and Phase I Clinical Trials
5. Quarterly Dividends, Clinical Trial Results, Dental Exhibition Updates, and Upcoming Presentation Schedules - Research Report Quest Diagnostics, Avanir, Sirona, Ligand and Genomic Health
6. Increased Dividends, Clinical Trial Results, Survey Results, and Updated Financial Guidance - Research Report on Aetna, Biogen, Eli Lilly, WellPoint, and Laboratory Corp. of America
7. Celsion Corporation Announces Combined Clinical Data from Two Phase I Trials at the 2013 San Antonio Breast Cancer Conference
8. Otonomy Doses First Subjects in Phase 3 Clinical Trials of OTO-201 in Pediatric Patients Undergoing Ear Tube Placement Surgery
9. BioLineRx Presents Positive Preclinical Results of Acute Myeloid Leukemia Treatment at ASH Conference
10. Array BioPharma Provides Clinical Update On ARRY-614 For Myelodysplastic Syndromes At The 2013 American Society Of Hematology Meeting
11. Integrated Safety and Efficacy Analysis of Phase 2 Clinical Trials of Pacritinib in Patients with Myelofibrosis and Low Platelet Counts Presented at ASH Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/18/2017)... April 18, 2017 Viverae ® , a ... the integration of IBM ® Watson Campaign Automation, ... targeted communications for a personalized experience. Through digital engagement, ... their health in real time. The enhanced experience drives ... to members, wherever they are in their journey to ...
(Date:4/18/2017)... , April 18, 2017  Astute Medical, Inc., ... case series to be presented at the 2017 National ... begins today and continues through April 22. Physicians will ... , used to assess risk for acute kidney injury ... heart failure (ADHF). Elevated levels of ...
(Date:4/18/2017)... 2017  Socionext Inc. and SOINN Inc. today ... in which Socionext extracts and delivers biometrics data ... initial results in reading ultrasound images from Socionext,s ... The results will be introduced at Medtec Japan, ... booths 4505 & 4507. In this ...
Breaking Medicine Technology:
(Date:4/29/2017)... ... April 29, 2017 , ... More than half of Americans suffering from ... in their leisure time that causes hearing loss? May 1 marks the beginning of ... to hearing loss, as well as schedule a hearing evaluation for anyone with concerns ...
(Date:4/28/2017)... ... April 28, 2017 , ... Accreditation Commission for Health Care ... of America (HCAOA). This agreement allows HCAOA members to receive special pricing on ... on Accreditation University (AU) educational resources that help prepare HCAOA members for ACHC ...
(Date:4/28/2017)... ... April 28, 2017 , ... Horizon Blue Cross Blue Shield of New Jersey ... “A” and its outlook as “stable.” At the same time, the ratings agency cautioned ... recent years, dip below “capital adequacy” thresholds required for its strong rating. , “Horizon ...
(Date:4/28/2017)... ... April 28, 2017 , ... ... tubes . These lamps offer an instant energy-saving solution for F32T8 fluorescent lamps ... fixtures or disconnect ballasts. These 50,000 hour rated lamps utilize the existing electronic ...
(Date:4/28/2017)... Texas (PRWEB) , ... April 28, 2017 , ... The ... plaque in recently to the labor and delivery team at Women’s Hospital at Renaissance ... mothers who give birth at the hospital and decide to donate. , “Women’s ...
Breaking Medicine News(10 mins):